Health-related Quality of Life in Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension

¹ 

关键词: Cardiology;    Rheumatology;    Psychosocial Issues;    Lifestyle Issues;    Social Work;    WHO Group 1- Pulmonary Arterial Hypertension;    PH Medications;    symptoms;    Research;    Qualityof Life;    Social Security Disability;    Exercise;    Cardiopulmonary rehabilitation;    Idiopathic (Primary pulmonary hypertension);    Associated Diseases;    Connective Tissue Diseases;    Scleroderma;    Oral therapy;    IV therapy;    Subcutaneous therapy;    Inhaled therapy;    Phosphodiesterase Inhibitors (PDE-5 Inhibitors);    Prostacyclin;    Endothelin Receptor Antagonists;    nitric oxide;    Diuretics;    Inotropes;    exercise hemodynamic testing;    6-Minute Walk Test;    Preserved ejection fraction;    endothelial dysfunction;    tricuspid regurgitation;    syncope;    dyspnea;    Functional Class;    patient-reported outcomes;    Drug development;    clinical trial;    Observational Studies;    CAMPHOR;    Education;    CEU;    Classification;    Epidemiology;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

【 摘 要 】

Response: POPH refers to the existence of pulmonary arterial hypertension that develops as a consequence of portal hypertension.1 Portopulmonary hypertension is internationally recognized within Group 1 of the 2008 Dana Point classification of pulmonary hypertension.2 Hemodynamically, POPH is defined by increased pulmonary vascular resistance (PVR) causing obstruction to arterial pulmonary flow as determined by right heart catheterization (RHC).

【 授权许可】

All Rights reserved